Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: A randomized, placebo-controlled study

T. Esfandyari, Michael Camilleri, I. Ferber, D. Burton, K. Baxter, A. R. Zinsmeister

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Cannabinoid receptor (CBR) stimulation inhibits motility and increases food intake in rodents. Effects of CBR stimulation in human gastrointestinal (GI) tract are unclear. We compared effects of dronabinol (DRO) and placebo (PLA) on GI transit, gastric volume and satiation in humans. In a double-blind, randomized study, 30 healthy volunteers were randomly assigned to DRO 5 mg b.i.d. or PLA for three doses. We measured GI functions noninvasively: day 0, Ensure® satiation test to measure maximum tolerated volume (MTV) and 30-min post-Ensure® symptoms; day 1, scintigraphic transit (111In-egg meal) and fasting and postprandial gastric volume (99Tcm-SPECT); day 2, 24-h colonic transit and repeat satiation test. ancova was used to compare treatment groups with gender, age, and, for the satiation test, the baseline MTV, as covariates. A log-rank test was used to assess treatment effects on gastric emptying. Planned sample size had 80% power to detect 25-30% differences in primary end points. There was an overall retardation of gastric emptying with DRO (P = 0.018); this was more pronounced in females (P = 0.011), than in males (P = 0.184). No significant treatment differences were detected for gastric volumes, MTV, post-Ensure® symptoms, small bowel and colonic transit. Fasting gastric volume was greater in males receiving DRO compared with PLA (238 ± 17 vs 185 ± 16, P = 0.04). DRO retards gastric emptying in humans; effects are gender-related. Dronabinol also increases fasting gastric volumes in males.

Original languageEnglish (US)
Pages (from-to)831-838
Number of pages8
JournalNeurogastroenterology and Motility
Volume18
Issue number9
DOIs
StatePublished - Sep 2006

Fingerprint

Gastrointestinal Transit
Satiation
Cannabinoid Receptor Agonists
Dronabinol
Healthy Volunteers
Placebos
Stomach
Gastric Emptying
Cannabinoid Receptors
Fasting
Placebo Effect
Single-Photon Emission-Computed Tomography
Double-Blind Method
Sample Size
Ovum
Meals
Gastrointestinal Tract
Rodentia
Therapeutics
Eating

Keywords

  • Accommodation
  • Colon
  • Dronabinol
  • Motility
  • Stomach
  • Transit

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology
  • Neuroscience(all)

Cite this

Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects : A randomized, placebo-controlled study. / Esfandyari, T.; Camilleri, Michael; Ferber, I.; Burton, D.; Baxter, K.; Zinsmeister, A. R.

In: Neurogastroenterology and Motility, Vol. 18, No. 9, 09.2006, p. 831-838.

Research output: Contribution to journalArticle

@article{5263db6a97154cc19e33b5e5a79e8428,
title = "Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: A randomized, placebo-controlled study",
abstract = "Cannabinoid receptor (CBR) stimulation inhibits motility and increases food intake in rodents. Effects of CBR stimulation in human gastrointestinal (GI) tract are unclear. We compared effects of dronabinol (DRO) and placebo (PLA) on GI transit, gastric volume and satiation in humans. In a double-blind, randomized study, 30 healthy volunteers were randomly assigned to DRO 5 mg b.i.d. or PLA for three doses. We measured GI functions noninvasively: day 0, Ensure{\circledR} satiation test to measure maximum tolerated volume (MTV) and 30-min post-Ensure{\circledR} symptoms; day 1, scintigraphic transit (111In-egg meal) and fasting and postprandial gastric volume (99Tcm-SPECT); day 2, 24-h colonic transit and repeat satiation test. ancova was used to compare treatment groups with gender, age, and, for the satiation test, the baseline MTV, as covariates. A log-rank test was used to assess treatment effects on gastric emptying. Planned sample size had 80{\%} power to detect 25-30{\%} differences in primary end points. There was an overall retardation of gastric emptying with DRO (P = 0.018); this was more pronounced in females (P = 0.011), than in males (P = 0.184). No significant treatment differences were detected for gastric volumes, MTV, post-Ensure{\circledR} symptoms, small bowel and colonic transit. Fasting gastric volume was greater in males receiving DRO compared with PLA (238 ± 17 vs 185 ± 16, P = 0.04). DRO retards gastric emptying in humans; effects are gender-related. Dronabinol also increases fasting gastric volumes in males.",
keywords = "Accommodation, Colon, Dronabinol, Motility, Stomach, Transit",
author = "T. Esfandyari and Michael Camilleri and I. Ferber and D. Burton and K. Baxter and Zinsmeister, {A. R.}",
year = "2006",
month = "9",
doi = "10.1111/j.1365-2982.2006.00834.x",
language = "English (US)",
volume = "18",
pages = "831--838",
journal = "Neurogastroenterology and Motility",
issn = "1350-1925",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects

T2 - A randomized, placebo-controlled study

AU - Esfandyari, T.

AU - Camilleri, Michael

AU - Ferber, I.

AU - Burton, D.

AU - Baxter, K.

AU - Zinsmeister, A. R.

PY - 2006/9

Y1 - 2006/9

N2 - Cannabinoid receptor (CBR) stimulation inhibits motility and increases food intake in rodents. Effects of CBR stimulation in human gastrointestinal (GI) tract are unclear. We compared effects of dronabinol (DRO) and placebo (PLA) on GI transit, gastric volume and satiation in humans. In a double-blind, randomized study, 30 healthy volunteers were randomly assigned to DRO 5 mg b.i.d. or PLA for three doses. We measured GI functions noninvasively: day 0, Ensure® satiation test to measure maximum tolerated volume (MTV) and 30-min post-Ensure® symptoms; day 1, scintigraphic transit (111In-egg meal) and fasting and postprandial gastric volume (99Tcm-SPECT); day 2, 24-h colonic transit and repeat satiation test. ancova was used to compare treatment groups with gender, age, and, for the satiation test, the baseline MTV, as covariates. A log-rank test was used to assess treatment effects on gastric emptying. Planned sample size had 80% power to detect 25-30% differences in primary end points. There was an overall retardation of gastric emptying with DRO (P = 0.018); this was more pronounced in females (P = 0.011), than in males (P = 0.184). No significant treatment differences were detected for gastric volumes, MTV, post-Ensure® symptoms, small bowel and colonic transit. Fasting gastric volume was greater in males receiving DRO compared with PLA (238 ± 17 vs 185 ± 16, P = 0.04). DRO retards gastric emptying in humans; effects are gender-related. Dronabinol also increases fasting gastric volumes in males.

AB - Cannabinoid receptor (CBR) stimulation inhibits motility and increases food intake in rodents. Effects of CBR stimulation in human gastrointestinal (GI) tract are unclear. We compared effects of dronabinol (DRO) and placebo (PLA) on GI transit, gastric volume and satiation in humans. In a double-blind, randomized study, 30 healthy volunteers were randomly assigned to DRO 5 mg b.i.d. or PLA for three doses. We measured GI functions noninvasively: day 0, Ensure® satiation test to measure maximum tolerated volume (MTV) and 30-min post-Ensure® symptoms; day 1, scintigraphic transit (111In-egg meal) and fasting and postprandial gastric volume (99Tcm-SPECT); day 2, 24-h colonic transit and repeat satiation test. ancova was used to compare treatment groups with gender, age, and, for the satiation test, the baseline MTV, as covariates. A log-rank test was used to assess treatment effects on gastric emptying. Planned sample size had 80% power to detect 25-30% differences in primary end points. There was an overall retardation of gastric emptying with DRO (P = 0.018); this was more pronounced in females (P = 0.011), than in males (P = 0.184). No significant treatment differences were detected for gastric volumes, MTV, post-Ensure® symptoms, small bowel and colonic transit. Fasting gastric volume was greater in males receiving DRO compared with PLA (238 ± 17 vs 185 ± 16, P = 0.04). DRO retards gastric emptying in humans; effects are gender-related. Dronabinol also increases fasting gastric volumes in males.

KW - Accommodation

KW - Colon

KW - Dronabinol

KW - Motility

KW - Stomach

KW - Transit

UR - http://www.scopus.com/inward/record.url?scp=33746878457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746878457&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2982.2006.00834.x

DO - 10.1111/j.1365-2982.2006.00834.x

M3 - Article

C2 - 16918762

AN - SCOPUS:33746878457

VL - 18

SP - 831

EP - 838

JO - Neurogastroenterology and Motility

JF - Neurogastroenterology and Motility

SN - 1350-1925

IS - 9

ER -